$MDGL News
Last published 5h ago
- 5h agoMDGLKaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law ViolationsGlobeNewswireKaplan Fox is investigating potential securities law violations by Madrigal Pharmaceuticals (NASDAQ: MDGL) after its stock fell on Nov. 3, 2026....
- 2d agoMDGLKaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law ViolationsGlobeNewswireNEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")
- 2d agoMDGLKaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law ViolationsGlobeNewswireKaplan Fox is investigating potential securities law violations by Madrigal Pharmaceuticals (NASDAQ: MDGL) after its stock fell on Nov. 3, 2026.
- 6d agoMDGLKaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law ViolationsGlobeNewswireNEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")
- 6d agoMDGLMadrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with RezdiffraGlobeNewswireIn real-world studies, up to 93% of patients experienced improvement or stabilization in liver stiffness with ultrasound elastography, with many patients moving into lower liver stiffness categories one year after
- 1w agoMDGLMADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewswireNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ:MDGL). The
- 1w agoMDGLMADRIGAL PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoMDGLMadrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireThird-quarter 2026 Rezdiffra® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability Rezdiffra reaches a major milestone, achieving blockbuster
- 1w agoMDGLMADRIGAL PHARMACEUTICAL Q3 2026 EARNINGS CALL - MADRIGAL PHARMACEUTICALS INCEarnings Call TranscriptsGood morning and thank you for standing by. Welcome to Madrigal Pharmaceuticals' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, th
- 2w agoMDGLMadrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASHGlobeNewswireRezdiffra® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapyReal-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in
- 3w agoMDGLMadrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026GlobeNewswireCONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to
- 3w agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 1mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 2mo agoMDGLMadrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewswireCONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept.
- 2mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 3mo agoMDGLMadrigal Appoints John C. Reed, M.D., Ph.D., to its Board of DirectorsGlobeNewswireCONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 3mo agoMDGLCG 46TH ANNUAL GROWTH CONFERENCE - MADRIGAL PHARMACEUTICALS INCEarnings Call TranscriptsHi, good afternoon everyone. My name is Edward Nash, senior biotech analyst here at Canaccord Genuity. It is my pleasure to have with us today the management team from Magical Pharmaceuticals. Joining us from the company
- 3mo agoMDGLCG 46TH ANNUAL GROWTH CONFERENCE - MADRIGAL PHARMACEUTICALS INCEarnings Call TranscriptsHi, good afternoon everyone. My name is Edward Nash, senior biotech analyst here at Canaccord Genuity. It is my pleasure to have with us today the management team from Magical Pharmaceuticals. Joining us from the company
- 3mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 3mo agoMDGLMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireCONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday,
- 3mo agoMDGLMadrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireSecond-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from 2Q25 reflecting
- 3mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 3mo agoMDGLMadrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026GlobeNewswireCONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the
- 4mo agoMDGLMadrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioGlobeNewswireReceived two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat
- 4mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 4mo agoMDGLRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHPR NewswireSuzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration...
- 4mo agoMDGLRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHPR NewswireSuzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration...
- 4mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 5mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 5mo agoMDGLMadrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026GlobeNewswireCONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on
- 5mo agoMDGLMadrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASHGlobeNewswireGrowing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles associated with
- 5mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 5mo agoMDGLMadrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskGlobeNewswireSecondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in patients with
- 6mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 6mo agoMDGLMadrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireFirst-quarter 2026 Rezdiffra® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued
- 6mo agoMDGLMadrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH PipelineGlobeNewswireCompany advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly
- 6mo agoARWRMDGLArrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal PharmaceuticalsBusiness Wire- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a
- 6mo agoMDGLMadrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026GlobeNewswireCONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the
- 6mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 7mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 7mo agoPRMEMDGLIOVADNLIThe $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepPR NewswireThe FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033. Cell...
- 7mo agoPRMEMDGLIOVADNLIAdvanced Cell-based Therapy Booming the Success for Healthcare SectorPR NewswireUSANewsGroup.com — The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578...
- 8mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 8mo agoMDGLMadrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireCONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March
- 8mo agoMDGLMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial ResultsGlobeNewswireFourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline
- 8mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
- 9mo agoMDGLRibo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHPR NewswireSuzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have...
- 9mo agoMDGLRibo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHPR NewswireSuzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have...
- 9mo agoMDGLMadrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA ProgramsGlobeNewswireCompany advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational
- 9mo agoMDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated